HANDSON AORTIC COURSE

Virgilio Usai (St Franziskus-Hospital Münster, Münster, Germany).

Commenting ahead of the symposium, Oderich, a member of the CX Aortic Executive Board, said: “We are all excited to see the latest advances in the arch and thoracoabdominal aorta, and for me personally, to learn from colleagues in Europe and the UK on what is going on there, and what I should change in my techniques.”

Highlights from day one include insights into advances in both open and endovascular thoracic aortic aneurysm (TAA) repair, options for the treatment of complex aortic pathologies, and a focus on the aortic dissection toolkit.

A podium first presentation from Kevin Mani (Uppsala University, Uppsala, Sweden) is among the highlights from the abdominal aortic session at the start of day two, exploring the benefits of statin treatment after aortic repair. The following juxtarenal aortic xxxx consensus update session includes discussion on the impact of the ETTAA (Effective treatments for thoracic aortic aneurysms) and UK-COMPASS (UK complex aneurysm) studies’ results with reference to National Institute for Health and Care Excellence (NICE) guidelines.

On rati des experum quiam quunt offic testotaturit rem harciis int, simusam quaero beatibus ium eatempos.

Thursday’s thoracic aortic consensus sessions close off the aortic programme with a debate on the conservative management of aortic intramural haematoma, featuring Michel Makaroun (University of Pittsburgh, Pittsburgh, USA) and Jean Panneton (Eastern Virginia Medical School, Norfolk, USA).

Treatment strategies for patients with chronic limb-threatening ischaemia (CLTI) have been firmly in the spotlight following the release of the first results from BEST-CLI in November 2022. CX will provide a platform to move the conversation forward, with firstto-podium results of the BASIL 2 randomised trial—comparing a ‘vein bypass first’ or a ‘best endovascular first’ revascularisation strategy—forming the centrepiece of a peripheral trial consensus update, taking place on the first day of the CX symposium.

During the session, BASIL 2 chief investigator Andrew Bradbury (University of Birmingham, Birmingham, UK) will deliver the first results from the trial, in a session that also sees participation from BEST-CLI investigators Matthew Menard (Brigham and Women’s Hospital, Boston, USA)—providing an update on the trial—and Alik Farber (Boston Medical Center, Boston, USA), presenting BEST-CLI quality-of-life data.

In-person attendees at CX 2023 will have the opportunity to attend a hands-on aortic workshop, led by Alexander Zimmermann (University of Zürich, Zürich, Switzerland), looking at the full range of fenestrated and branched endografts, including devices that are physician-modified. The workshop will provide attendees with the opportunity to expand their knowledge and test and improve their skills in a practical session. Offering a deep dive into physician-modified stent grafts, this interactive demonstration will explore the theory behind the history and indications of these devices, and the techniques employed to create fenestrations and branches.